180 related articles for article (PubMed ID: 14754434)
1. Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance.
Blower S; Ma L; Farmer P; Koenig S
Curr Drug Targets Infect Disord; 2003 Dec; 3(4):345-53. PubMed ID: 14754434
[TBL] [Abstract][Full Text] [Related]
2. Designing equitable antiretroviral allocation strategies in resource-constrained countries.
Wilson DP; Blower SM
PLoS Med; 2005 Feb; 2(2):e50. PubMed ID: 15737005
[TBL] [Abstract][Full Text] [Related]
3. Ethical use of antiretroviral resources for HIV prevention in resource poor settings.
Rennie S
Dev World Bioeth; 2013 Aug; 13(2):79-86. PubMed ID: 23724978
[TBL] [Abstract][Full Text] [Related]
4. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.
Holmes CB; Coggin W; Jamieson D; Mihm H; Granich R; Savio P; Hope M; Ryan C; Moloney-Kitts M; Goosby EP; Dybul M
JAMA; 2010 Jul; 304(3):313-20. PubMed ID: 20639565
[TBL] [Abstract][Full Text] [Related]
5. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco.
Smith RJ; Okano JT; Kahn JS; Bodine EN; Blower S
Science; 2010 Feb; 327(5966):697-701. PubMed ID: 20075214
[TBL] [Abstract][Full Text] [Related]
6. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
7. From modeling to morals: imagining the future of HIV PREP in Lesotho.
Kenworthy NJ; Bulled N
Dev World Bioeth; 2013 Aug; 13(2):70-8. PubMed ID: 23800326
[TBL] [Abstract][Full Text] [Related]
8. Separate goals, converging priorities: on the ethics of treatment as prevention.
Ostmann F; Saenz C
Dev World Bioeth; 2013 Aug; 13(2):57-62. PubMed ID: 23800304
[TBL] [Abstract][Full Text] [Related]
9. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models.
Blower S; Bodine E; Kahn J; McFarland W
AIDS; 2005 Jan; 19(1):1-14. PubMed ID: 15627028
[TBL] [Abstract][Full Text] [Related]
10. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
[TBL] [Abstract][Full Text] [Related]
11. Long-Acting Formulations for the Prevention and Treatment of Human Immunodeficiency Virus (HIV)-1 Infection: Strategic Leveraging and Integration of Multidisciplinary Knowledge to Advance Public Health.
Arya V; Hodowanec AC; Troy SB; Struble KA
Clin Infect Dis; 2022 Nov; 75(Suppl 4):S498-S501. PubMed ID: 36410378
[TBL] [Abstract][Full Text] [Related]
12. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?
Velasco-Hernandez JX; Gershengorn HB; Blower SM
Lancet Infect Dis; 2002 Aug; 2(8):487-93. PubMed ID: 12150848
[TBL] [Abstract][Full Text] [Related]
13. Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings.
Cambiano V; Bertagnolio S; Jordan MR; Lundgren JD; Phillips A
J Infect Dis; 2013 Jun; 207 Suppl 2():S57-62. PubMed ID: 23687290
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study - PEDA Study.
Sapsirisavat V; Vongsutilers V; Thammajaruk N; Pussadee K; Riyaten P; Kerr S; Avihingsanon A; Phanuphak P; Ruxrungtham K;
PLoS One; 2016; 11(6):e0157039. PubMed ID: 27322409
[TBL] [Abstract][Full Text] [Related]
15. Preventing HIV transmission with antiretrovirals.
De Cock KM; Crowley SP; Lo YR; Granich RM; Williams BG
Bull World Health Organ; 2009 Jul; 87(7):488-488A. PubMed ID: 19649357
[No Abstract] [Full Text] [Related]
16. Factors influencing global antiretroviral procurement prices.
Wirtz VJ; Forsythe S; Valencia-Mendoza A; Bautista-Arredondo S
BMC Public Health; 2009 Nov; 9 Suppl 1(Suppl 1):S6. PubMed ID: 19922690
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluations of HIV prevention in rich countries and the need to focus on the aging of the HIV-positive population.
Brent RJ; Brennan M; Karpiak SE
Curr Opin HIV AIDS; 2010 May; 5(3):255-60. PubMed ID: 20539083
[TBL] [Abstract][Full Text] [Related]
18. Safety of antiretroviral drug therapy in Jamaican children with HIV/AIDS.
Pryce C; Pierre RB; Steel-Duncan J; Evans-Gilbert T; Palmer P; Moore J; Rodriguez B; Christie CD
West Indian Med J; 2008 Jun; 57(3):238-45. PubMed ID: 19583122
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.
De Luca A; Hamers RL; Schapiro JM
J Infect Dis; 2013 Jun; 207 Suppl 2():S63-9. PubMed ID: 23687291
[TBL] [Abstract][Full Text] [Related]
20. Impact of new developments in antiretroviral treatment on AIDS prevention and care in resource-poor countries.
Colebunders R; Verdonck K; Nachega J; Kothari P
AIDS Patient Care STDS; 2000 May; 14(5):251-7. PubMed ID: 10833812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
